Stuart Fletcher is Chief Executive Officer of Bupa, the global health and care company, a role he has held since March 2012.
Bupa is a leading global health and care group providing health insurance, medical subscriptions services, care homes, hospitals, clinics, dentistry and a range of other health and care services. With almost 80,000 people in operations around the world dedicated to having people live longer, healthier, happier lives, the company’s no-shareholder status allows it to reinvest its surplus to provide more and better healthcare.
Bupa achieved revenues of £9.8 billion and profits of £637.8 million in 2014, has 29 million customers in over 190 countries and almost 80,000 employees.
Stuart was previously President, Diageo International between 2004-2011, having been President, Key Markets 2000-2004. Stuart held a number of other senior management positions at Diageo, joining the company in 1986, including as Global Finance Director, Guinness. Previously Stuart held various financial roles with Procter & Gamble.
As technology continues to advance and the role of the patient increases in healthcare delivery, the entire ecosystem requires a fundamental change. In this panel, our experts provide a glimpse into the exciting future in store for patients, but also seek to understand the challenges to unlocking medical value through technology. In this new “customer-centric” world, how will patients interact with the physician and the healthcare eco-system and will patient access, outcomes and affordability actually improve? Are life science companies capable of executing “beyond the pill” strategies? Will medical professionals be able to shift from traditional models of delivery to a technology led and data driven system? How is healthcare delivery changing, and what can we look forward to in the coming decade?
After a generation of rising R&D costs and declining productivity, new R&D models have emerged. Scientific and technological innovations are bringing excitement back to the pharma and biotech industry. R&D is now driving the new business model that sees life science companies move away from ‘blockbuster’ one size fits all symptomatic treatments to targeted disease modifying treatments. With high prices and regulatory incentives, breakthroughs in treatments for rare diseases are now also on the agenda of many of the top pharmaceutical companies and promise to deliver fresh growth. R&D has recently responded to some of the healthcare industry’s greatest challenges, from cancer to infectious diseases such as Ebola. Therefore with resurgent pipelines and major breakthroughs in R&D, our panel will explore how R&D is changing and becoming more productive in a constantly evolving healthcare landscape.
Dr. Paul Stoffels is Chief Scientific Officer, Johnson & Johnson. In this role, he works with R&D leaders across Johnson & Johnson to set the enterprise-wide innovation agenda and is a member of the Johnson & Johnson Executive Committee.
Paul chairs the Johnson & Johnson R&D Management Committee and provides oversight to the Johnson & Johnson Development Corporation (JJDC) and the Johnson & Johnson Innovation centers, with the goal of catalyzing innovative science and technology. Additionally, Paul has oversight for product safety of all products of the Johnson & Johnson Family of Companies worldwide.
Paul also is Worldwide Chairman, Pharmaceuticals, Johnson & Johnson, with responsibility for expansion of the company’s therapeutic pipeline through global R&D and strategic partnerships, licensing and acquisitions. He oversees teams across the Janssen Pharmaceutical Companies of Johnson & Johnson, which discover and develop treatments for unmet medical needs in the therapeutic areas of cardiovascular & metabolism, immunology, infectious disease &vaccines;, neuroscience and oncology.
Prior to his role as Worldwide Chairman, he served as Global Head, Johnson & Johnson Pharmaceutical R&D from 2009 - 2011, as Company Group Chairman, Central Nervous System & Internal Medicine, from 2006 - 2009, and as Company Group Chairman, Global Virology, from 2005-2006. Paul joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and as Chairman of Tibotec, and led the development of a number of leading products for the treatment of HIV.
Paul studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium. He began his career as a physician in Africa, focusing on HIV and tropical diseases research.